Anika Therapeutics, Inc. Proceeds from Long-Term Debt Issued
Anika Therapeutics, Inc. (ANIK) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2023-03-16
- Anika Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00.
- Anika Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2021-09-30 was $0.00.
- Anika Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2020-12-31 was $0.00.
- Anika Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2020-09-30 was $0.00.
- Anika Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2022 was $0.00.
- Anika Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Anika Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2020 was $50.00M.
- Anika Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2019 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 10-K · filed 2023-03-16 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $50.00M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $50.00M 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $50.00M 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $0.00 10-K/A · filed 2021-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |